DNA methylation: Advances in methylomics and the importance of strandedness

By: Roche Life Science

Posted: May 02, 2016 | Lab Life - Epigenetics

It has been nearly 12 years since the landmark publication of the first complete sequence of the entire human genome1. Indeed, the post human genome-sequencing era has seen exponential advances in large-scale genomic analyses that have paved the way for systematic evaluation of epigenetic modifications—including mapping DNA regulatory elements as well as genome-wide modifications such as DNA methylation and histone post-translational modifications—at the global (or epigenomic) level. With today's cutting edge technological advancements in high throughput methods to assess DNA methylation status at single-base resolution, researchers are obtaining groundbreaking data at flurried pace. Indeed, recent in-depth methylomic analyses have highlighted a previously unaddressed issue in epigenetic analysis—that of strand bias, or strandedness. In this article, we will review some of the basic principles of DNA methylation and discuss some of the recent data describing the biologic importance of understanding strand-bias in dynamic DNA methylation patterns.

DNA methylation—the basics

DNA methylation can occur at cytosine or adenine nucleotides—although the latter is restricted to prokaryotic cells. Cytosine DNA methylation occurs at the fifth position of cytosine (5mC) and is an evolutionarily conserved process that creates a heritable, covalent epigenetic modification to DNA. It is estimated that only a small percentage of cytosines are methylated in human DNA (approximately 3 percent)2. While classically associated with gene silencing functions, we now understand that DNA methylation has a much more complex and dynamic regulatory role and is involved in diverse biological processes, including genomic imprinting, tumorigenesis, gene and transposon silencing, formation of chromatin structure, as well as X chromosome inactivation3.

DNA methylation in mammalian cells generally occurs at CpG dinucleotide sites via the conserved DNA methyltransferases family—including DNA methyltransferase 1 (DNMT1), DNMT3A, and DNMT3B. While the propogation of DNA methylation patterns is generally mediated by DNMT1, DNMT3A and DNMT3B are thought to regulate more dynamic methylation patterns, including de novo methylation sites3,4. Indeed, it is estimated that genome-wide, approximately 60-80% of the nearly 28 million CpG dinucleotides are methylated5. And while the majority of genomic DNA methylation patterns remain static, there are notable exceptions of dynamic and global methylation reprogramming in germ cells, pre-implantation embryos, embryonic stem cells (ESC), induced pluripotent stem cells (iPSC), and even brain cells3,4,6-8. Indeed, dynamic and active enzymatic regulation of mammalian DNA demethylation was found to occur via the conversion of 5mC to 5-hydroxymethylcytosine (5hmC) by the ten-eleven translocation (TET) family of dioxygenases9.

Advances in methylomics

The translation of next-generation sequencing (NGS) technology to epigenomic analysis has propelled our understanding of DNA methylation by allowing determination of methylated cytosines at single base pair resolution in a strand-specific manner. This includes strategies such as whole genome bisulfite sequencing or target enrichment of bisulfite treated DNA. And while active methylation patterns have been elucidated in embryonic and pluripotent stem cells, scientists have only recently began to understand the complex role of DNA methylation changes in human disease.

While early data revealed the role of cytosine methylation in increased rates of germline C→T transitions within coding regions of disease-relevant genes10, recent studies have demonstrated aberrant de novo hypermethylation and global hypomethylation patterns in gene promoter regions of various tumor suppressor genes in a number of human cancer methylomes. These changes are thought to result in irreversible gene silencing and subsequent associated chromosomal instability11,12.

Strandedness in methylation

Historically, CpG sites have been presumed to have symmetric methylation. However, recent studies have determined that there are strand specific differences in both CpG and non-CpG methylation sites13,14.  For instance, bisulfite PCR sequencing of both sense and anti-sense strands of the adenomatous polyposis coli (APC) tumor suppressor gene in hepatocellular carcinoma (HCC) samples revealed anti-sense strand-biased CpG methylation changes in a liver-specific manner13.

Non-CpG methylation predominantly occurs in embryonic stem cells (ESCs), induced pluripotent stem cells (iPSCs), oocytes and brain cells, however the precise function of such epigenetic marks remains elusive. Analysis of the strand-specific distribution of non-CpG methylation in human ESCs and iPSCs using a divide-and-compare strategy revealed strand-specific asymmetry. In particular, there was asymmetry in non-CpG methylation at intron boundaries in high-expressing genes as well in subgroups of transposable elements, including short interspersed nuclear elements (SINE) and long interspersed nuclear elements (LINE), but not in long terminal repeats (LTR)14. In male murine germ cells, non-CpG methylation accumulates around the B1 retrotransposon sequences in mitotically arrested fetal prospermatogonia in a Dnmt3I-dependent manner. The preferential site of non-CpG methylation occurred at CpA sites via a non-template-dependent copying mechanism following hairpin-bisulfate sequencing analysis15.

Together, these advancements in next-generation methylomics have only just begun to reveal the intricate and dynamic complexities of non-classical CpG and non-CpG methylation patterns. Importantly, discovering how these modifications contribute to embryonic development, cellular differentiation, and disease pathogenesis will provide enormous scientific advancements in our understanding of epigenomics.

1. International Human Genome Consortium. Finishing the euchromatic sequence of the human genome. Nature 431, 931–945 (2004).
2. Strachan T and Read A. Human Molecular Genetics, 4th edition. Garland Science 2011.
3. Law JA et al. Establishing, maintaining and modifying DNA methylation patterns in plants and animals. Nat Rev Genet (2010). 11 (3): 204-220.
4. Smith ZD et al. DNA methylation: roles in mammalian development. Nat Rev Genet (2013). 14, 204-2013.
5. Ehrlich M et al. Amount and distribution of 5-methylcytosine in human DNA from different types of tissues of cells. Nucleic acids research (1982). 10: 2701-21.
6. Ziller MJ et al. Genomic distribution and inter-sample variation of non-CpG methylation across human cell types. PLoS Genet. 2011;7:e1002389.
7. Lister R et al. Global epigenomic reconfiguration during mammalian brain development. Science 2013; 341:1237905
8. Messerschmidt et al. DNA methylation dynamics during epigenetic reprogramming in the germline and preimplantation embryos. Genes & Dev (2014). 28: 812-838.
9. Tahiliani et al. Conversion of 5-methylcytosine to 5-hydroxymethylcytosine in mammalian DNA by MLL partner TET1. Science (2009) 324: 930–935.
10. Cooper et al. The CpG dinucleotide and human genetic disease. Hum Genet (1988) 78, 151-155.
11. Weisenberger DJ et al. Contributions of DNA methylation aberrancies in shaping the cancer epigenome. Trans Canc Res (2015) 4 (3): 219-234.
12. Jones PA. Functions of DNA methylation: islands, start sites, gene bodies and beyond. Nat Rev Genet (2012). 13 (7): 484-92.
13. Jain S et al. Methylation of the CpG sites only on the sense strand of the APC gene is specific for hepatocellular carcinoma. PLoS One. 2011;6(11):e26799.
14. Guo W et al. Characterizing the strand-specific distribution of non-CpG methylation in human pluripotent cells. Nucleic Acids Res. 2014 Mar;42(5):3009-16.
15. Ichiyanagi T et al. Accumulation and loss of asymmetric non-CpG methylation during male germ-cell development. Nucleic Acids Res. 2013 Jan;41(2):738-45.


  • Facebook Publish Icon
Share via E-Mail

Got an idea?

We want to hear from you! What are most curious to learn about? What would you like to ask our Roche Scientists? Let your voice be heard!